Exposure to Organophosphates Reduces the Expression of Neurotrophic Factors in Neonatal Rat Brain Regions: Similarities and Differences in the Effects of Chlorpyrifos and Diazinon on the Fibroblast Growth Factor Superfamily by Slotkin, Theodore A. et al.
The developmental neurotoxicity of organo-
phosphate pesticides represents a biological
conundrum that has important ramiﬁcations
for human exposures (for review see Colborn
2006; Costa 2006; Landrigan 2001; Mileson
et al. 1998; Slotkin 2005; Weiss et al. 2004).
All of the organophosphates produce systemic
toxicity by inhibiting acetylcholinesterase,
resulting in overt symptoms of cholinergic
hyperstimulation; these effects have therefore
been assumed to be the common mechanism
underlying adverse developmental conse-
quences (Mileson et al. 1998). However, the
fetus and neonate recover from cholinesterase
inhibition much more quickly than adults
(Chakraborti et al. 1993; Lassiter et al. 1998),
yet display greater overall toxicity and damage
to the central nervous system (for review see
Pope 1999; Slotkin 2004, 2005). Indeed,
evidence accumulating over the past decade
implicates a host of other mechanisms in
the developmental neurotoxicity of the
organophosphates that depend instead upon
the direct targeting of events specific to the
developing brain (for review see Barone et al.
2000; Pope 1999; Rice and Barone 2000;
Slotkin 2004). Importantly, many of these
processes are vulnerable to organophosphates
at doses below those necessary to elicit signs of
systemic toxicity and even below the threshold
for significant inhibition of cholinesterase
(Pope 1999; Slotkin 2004, 2005).
Although a wide variety of intermediate
events in brain development connect the ini-
tial effects of organophosphates on neural cell
differentiation to the eventual synaptic and
behavioral defects (Pope 1999; Slotkin 2004,
2005), little information is currently available
about speciﬁc cellular mechanisms that render
the developing brain so vulnerable to these
agents. Indeed, many events in differentiation
and assembly of neural circuits are affected,
including the processes of neuronal and glial
cell replication and differentiation, speciﬁca-
tion of neurotransmitter phenotypes, axono-
genesis and synaptogenesis, and synaptic
function (Barone et al. 2000; Casida and
Quistad 2004; Gupta 2004; Jameson et al.
2006; Pope 1999; Slotkin 1999, 2004). In
turn, the diversity of these targets suggests that
the organophosphates disrupt some very basic
processes in neural cell differentiation. For
that reason, a number of investigations have
turned to the neurotrophic factors known to
play critical roles in neural development and
damage/repair processes. 
In adults, fully symptomatic organo-
phosphate poisoning produces peripheral
neuropathies and then a reactive increase in
formation of neurotrophic factors mediating
repair and neuritic outgrowth (Pope et al.
1995). Although we are dealing with events in
the central nervous system rather than with
peripheral neuropathies, it is not unreasonable
to hypothesize that these factors are equally or
even more important at the subtoxic exposures
that damage the developing brain. Two sets of
neurotrophic factors have been explored to
date. First, acetylcholinesterase itself is thought
to play a nonenzymatic role in neural develop-
ment (Brimijoin and Koenigsberger 1999),
and we recently demonstrated induction of the
neurotoxic splice variant of acetylcholinesterase
at organophosphate exposures below the
threshold for detectable inhibition of enzy-
matic activity in neonatal rat brain after
apparently subtoxic exposures to chlorpyrifos
or diazinon (Jameson et al. 2007). In addi-
tion, two recent studies (Betancourt and Carr
2004; Betancourt et al. 2006) focused on
nerve growth factor and brain-derived neuro-
trophic factor after exposure of newborn rats
to chlorpyrifos or chlorpyrifos oxon, the active
metabolite that inhibits cholinesterase.
Although these researchers used exposures that
were above the threshold for cholinesterase
inhibition and somatic growth impairment,
they found no significant decrease in either
protein (Betancourt and Carr 2004) and only
a small decrease (10–20%) in the mRNA
encoding nerve growth factor (Betancourt
et al. 2006).
Thus, if organophosphate effects on
neurotrophic factors play an important role in
the developmental neurotoxicity of these
agents, then other factors are likely to be more
highly affected. In the present study, we
turned our attention to the large number of
fibroblast growth factors (FGFs) and their
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BACKGROUND: The ﬁbroblast growth factor (FGF) superfamily of neurotrophic factors plays critical
roles in neural cell development, brain assembly, and recovery from neuronal injury. 
OBJECTIVES: We administered two organophosphate pesticides, chlorpyrifos and diazinon, to
neonatal rats on postnatal days 1–4, using doses below the threshold for systemic toxicity or growth
impairment, and spanning the threshold for barely detectable cholinesterase inhibition:
1 mg/kg/day chlorpyrifos and 1 or 2 mg/kg/day diazinon. 
METHODS: Using microarrays, we then examined the regional expression of mRNAs encoding the
FGFs and their receptors (FGFRs) in the forebrain and brain stem. 
RESULTS: Chlorpyrifos and diazinon both markedly suppressed fgf20 expression in the forebrain
and fgf2 in the brain stem, while elevating brain stem fgfr4 and evoking a small deﬁcit in brain stem
fgf22. However, they differed in that the effects on fgf2 and fgfr4 were signiﬁcantly larger for diazi-
non, and the two agents also showed dissimilar, smaller effects on fgf11, fgf14, and fgfr1. 
CONCLUSIONS: The fact that there are similarities but also notable disparities in the responses to
chlorpyrifos and diazinon, and that robust effects were seen even at doses that do not inhibit
cholinesterase, supports the idea that organophosphates differ in their propensity to elicit develop-
mental neurotoxicity, unrelated to their anticholinesterase activity. Effects on neurotrophic factors
provide a mechanistic link between organophosphate injury to developing neurons and the even-
tual, adverse neurodevelopmental outcomes.
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plays a widespread and vital role in brain
development and in the repair from neural
injury (Dono 2003). Across the various stages
of development, the FGFs promote and main-
tain neuronal cell replication and are required
for differentiation into the terminal transmit-
ter phenotype (Gage et al. 1995; Johe et al.
1996). The different FGFs play speciﬁc roles
in neuronal cell differentiation, neurite out-
growth, and the recovery from damage in
regions such as the striatum and hippocampus
(Hart et al. 2000; Limke et al. 2003; Murase
and McKay 2006; Ohmachi et al. 2000; Ray
et al. 1993; Takagi et al. 2005). The same
regions are known targets for the adverse neuro-
developmental effects of organophosphates
(Barone et al. 2000; Slotkin 1999, 2004,
2005), which disrupt the very same cellular
events for which the FGFs provide trophic sig-
nals (Axelrad et al. 2003; Das and Barone
1999; Howard et al. 2005; Song et al. 1998).
Accordingly, we used a microarray approach to
examine the family of FGFs and their recep-
tors, comparing the effects of two different
organophosphates, chlorpyrifos and diazinon,
to emphasize points of similarity and differ-
ence: if the developmental neurotoxicity of the
organophosphates involves neurotrophic
mechanisms unrelated to the inhibition of
cholinesterase, then there may be significant
disparities in their impact on neurotrophic fac-
tors. We concentrated on doses that evoke
barely detectable inhibition, too low to elicit
any signs of cholinergic hyperstimulation
(Slotkin et al. 2006b; Song et al. 1997); our
assessments were conducted in two brain
regions, the brain stem and forebrain, that dif-
fer both in anatomical attributes as well as in
maturational timetables (Rodier 1988).
Materials and Methods
Animal treatments. All experiments were car-
ried out in accordance with federal and state
guidelines and with prior approval of the
Duke University Institutional Animal Care
and Use Committee; all animals were treated
humanely and with due care for alleviation of
distress. Timed-pregnant Sprague-Dawley
rats (Charles River, Raleigh, NC, USA) were
housed in breeding cages, with a 12-hr
light/dark cycle and free access to food and
water. On the day of birth, all pups were ran-
domized and redistributed to the dams with a
litter size of 9–10 to maintain a standard
nutritional status. 
Chlorpyrifos and diazinon (both from
Chem Service, West Chester, PA, USA) were
dissolved in dimethylsulfoxide to provide con-
sistent absorption (Whitney et al. 1995), and
were injected subcutaneously in a volume of
1 mL/kg body weight once daily on postnatal
days (PNDs) 1–4; control animals received
equivalent injections of dimethylsulfoxide
vehicle. For both agents, we used doses below
the threshold for growth retardation and sys-
temic toxicity (Campbell et al. 1997; Slotkin
et al. 2006a; Whitney et al. 1995): 1 mg/kg
for chlorpyrifos and either 1 or 2 mg/kg for
diazinon. This chlorpyrifos treatment and the
higher dose of diazinon produce neurotoxicity
in developing rat brain while eliciting < 20%
cholinesterase inhibition, whereas the lower
dose of diazinon does not produce any
detectable inhibition (Slotkin 1999, 2004;
Slotkin et al. 2006b; Song et al. 1997;
Whitney et al. 1995), or any of the symptoms
of cholinergic hyperstimulation known to be
characteristic of anticholinesterase activity
(Clegg and van Gemert 1999). These treat-
ments thus resemble the nonsymptomatic
exposures reported in pregnant women
(De Peyster et al. 1993) and are within the
range of expected fetal and childhood expo-
sures after routine home application or in
agricultural communities (Gurunathan et al.
1998; Ostrea et al. 2002). 
On PND5 (24 hr after the last dose), one
male pup was selected from each of ﬁve litters
in each treatment group. Animals were decap-
itated, the cerebellum was removed, and the
brain stem and forebrain were separated by a
cut made rostral to the thalamus. Tissues were
weighed and flash-frozen in liquid nitrogen
and maintained at –45°C until analyzed. Our
study design involved the analysis of 40 sepa-
rate tissues: one animal from each of ﬁve lit-
ters for each of the four treatment groups,
with two tissues (brain stem, forebrain) from
each animal.
Microarray determinations. Tissues were
thawed and total RNA was isolated using the
Aurum total RNA Fatty and Fibrous Tissue
Kit (Bio-Rad Laboratories, Hercules, CA,
USA). RNA quality was verified using the
RNA 6000 LabChip Kit and the Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto,
CA, USA). An aliquot of each sample used in
the study was withdrawn and combined to
make a reference RNA preparation to be
included on each array. RNA amplification
was carried out using a commercial kit (Low
RNA Input Fluorescent Linear Ampliﬁcation
Kit; Agilent). 
Each RNA sample was annealed with a
primer containing a polydT and a T7 poly-
merase promoter. Reverse transcriptase pro-
duced a first and second strand cDNA. T7
RNA polymerase then created cRNA from
the double stranded cDNA by incorporating
cyanine-3– (for the reference RNA) or cya-
nine-5– (for the sample RNA) labeled cyti-
dine 5-triphosphate; the quality of the labeled
cRNA was again verified and the absolute
concentration was measured spectrophoto-
metrically. For each pair of reference cRNA
and experimental cRNA hybridized to an
array, equal amounts of cRNA (0.75 µg) were
hybridized using a commercial kit (In situ
Hybridization Kit-Plus; Agilent). Hybridiza-
tion was performed at 60°C for 17 hr with
Agilent Whole Rat Genome Arrays (G4131A).
The arrays were washed with Agilent’s SSPE
Wash Protocol using a solution of 6× SSPE,
0.005% N-lauroylsarcosine, a solution of
0.06× SSPE, 0.005% N-lauroylsarcosine, and
Agilent’s Stabilization and Drying Solution.
The arrays were scanned on an Agilent
G2565BA Microarray Scanner, and data from
the scans were compiled with Agilent Feature
Extraction Software 8.1. The steps from RNA
ampliﬁcation through extraction of the scanner
output data were performed by a private con-
tractor (Cogenics, Research Triangle Park,
NC, USA).
Array normalizations and error detection
were carried out using Silicon Genetics’
GeneSpring GX Version 7.2 (Agilent), via the
Enhanced Agilent Feature Extraction Import
Preprocessor. First, values of poor quality
intensity and low dependability were removed
using a “filter on flags” feature, where stan-
dardized software algorithms determined
which spots were “present,” “marginal,” or
“absent”; spots were considered “present” only
where the output was uniform, not saturated
and significant above background, whereas
spots that satisﬁed the main requirements but
were outliers relative to the typical values for
the other genes were considered “marginal.”
Filters were set to retain only the values that
were found to be present or marginal for fur-
ther analysis; however, of the genes that passed
the ﬁlter, none was marginal.
Data were normalized in three steps using
the algorithms supplied with the Feature
Extraction software. The ﬁrst step divides the
signal in the Cy5 channel (sample RNA) by
that in the Cy3 channel (reference RNA), to
give the measured ratio for each gene in the
array. The second normalization adjusts the
total signal of each chip to a standard value
(“normalize to 50th percentile”) determined by
the median of all the reliable values on the
chip; this renders the output of each chip com-
parable with that of every other chip in the
study. The third normalization step is applied
to each gene across all the arrays in the study
(“normalize to median”): The median of all the
values obtained for a given gene is calculated
and used as the normalization standard for that
gene, so that, regardless of absolute differences
in the expression of the various genes, they are
placed on the same scale for comparison.
After normalization, one final quality-
control ﬁlter was applied in which genes show-
ing excessive biologic variability were discarded;
the criterion for retention was that more than
half of the eight treatment × region groupings
had to have coefﬁcients of variation < 30%.
For some of the genes, the arrays con-
tained multiple probes and/or replicates of the
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and these were used to verify the reliability of
values and the validity of the measures on the
chip. In these cases, to avoid artiﬁcially inﬂat-
ing the number of positive ﬁndings, we limited
each gene to a single set of values, selecting
those obtained for the probe showing the
smallest intragroup (treatment, region) vari-
ance; the other values for that gene were used
only to corroborate direction and magnitude
of change. Through these procedures we iden-
tiﬁed ﬁve defective arrays with sequential pro-
duction numbers, for which one corner of the
array showed a nonuniform overall difference
in brightness that affected the readings in that
region of the chip. The affected samples were
reevaluated on replacement arrays that did not
repeat the problem. Our experimental design
ensured that the replacement readings were
distributed among all the treatment groups
because our sample sequence was control,
chlorpyrifos, diazinon 1 mg/kg, diazinon
2 mg/kg; thus we did not run the risk of gen-
erating a spurious apparent treatment effect
from differences among arrays. The defective
arrays did allow us to perform an additional
quality-control evaluation because most of the
spots on the defective arrays were in the por-
tion that did not show the defect. Comparing
the values on the replacement arrays to the
valid portions of the defective arrays produced
a close correspondence of values (correlation
coefﬁcient = 0.98).
Statistical procedures. Because of the
requirement to normalize the data across
arrays and within each gene, the absolute val-
ues for a given gene are meaningless; only the
relative differences between regions and treat-
ments can be compared. Accordingly, results
for the regional differences in gene expression
in control rats are presented as means ± SEs of
the normalized ratios for each gene, but the
effects of the treatments are given as the per-
centage change from control to allow for
visual comparison of the relative changes
evoked for each gene, regardless of its control
ratio. However, statistical comparisons were
based on the actual ratios (log-transformed
because the data are in the form of ratios)
rather than the percent change.
Our design involved planned comparisons
of the organophosphate-exposed groups to
the controls and between the two different
organophosphates, so it was important to
consider the false positive rate and to protect
against type 1 errors from repeated testing of
the same database. Accordingly, before look-
ing at effects on individual genes, we per-
formed a global analysis of variance (ANOVA)
incorporating all treatments, both regions,
and all genes in a single comparison. Lower-
order ANOVAs were then carried out as per-
mitted by the interactions of treatment with
region and gene that justiﬁed subdivisions of
the data set. Finally, differences for individual
treatments for a speciﬁed gene in a single brain
region were evaluated with Fisher’s protected
least significant difference test. However,
where there was no treatment × region inter-
action for a given gene; only the main treat-
ment effect was reported without subtesting of
effects in individual regions. For ANOVA
results, effects were considered significant at
p < 0.05 (two-tailed, because we were inter-
ested in both increases and decreases in gene
expression). In addition to these parametric
tests of the direction and magnitude of
changes in gene expression, we evaluated the
incidence of significant differences as com-
pared with the false positive rate using Fisher’s
exact test, applying a one-tailed criterion of
p < 0.05 because only an increase above the
false positive rate would be predicted. Finding
a significant decrease in the incidence of
detected differences relative to the false posi-
tive rate would be biologically implausible and
statistically meaningless.
Results
Of the FGF and FGFR genes present on the
microarray, 19 genes passed the quality control
filters, encoding 15 of the FGFs and all 4
FGFRs (Table 1). In control rats, we did not
observe any overall pattern of regional prefer-
ence for expression of these genes: Of the
19 genes evaluated, only 6 showed signiﬁcant
regional differences, with fgf9, fgf22, and fgfr2
more highly expressed in the brain stem,
whereas fgf14, fgf20, and fgfr1 were higher in
the forebrain. Organophosphate exposures
elicited signiﬁcant, regionally selective changes
in gene expression for the FGFs and FGFRs.
Multivariate ANOVA (all treatments, all
genes, both regions) showed a signiﬁcant treat-
ment × region × gene interaction (p < 0.0001),
enabling separate evaluations for each gene.
Out of the 19 genes, 7 displayed significant
main treatment effects or an interaction of
treatment × region, as compared with an
expected false positive rate of only 1 gene
(p < 0.02).
For the genes encoding FGFs, chlorpyri-
fos exposure produced a significant overall
decrement (main treatment effect, p < 0.05)
and specific reductions in the expression of
fgf2, fgf11, fgf20, and fgf22 (Figure 1). By far,
the largest effect was on fgf20, which showed
a 50% deﬁcit in the forebrain; this region also
displayed a significant deficit in fgf2 and
fgf11. In contrast, the brain stem showed
smaller decreases restricted to fgf2 and fgf22.
The effects of diazinon on the FGF genes
displayed similarities to those of chlorpyrifos,
but also some differences. The lower dose of
diazinon caused a large reduction in forebrain
fgf20 expression as did chlorpyrifos, but diazi-
non failed to decrease forebrain fgf2 or fgf11
signiﬁcantly, and instead evoked a reduction
in fgf14 (Figure 2A). In the brain stem, we
again saw a small decrease in fgf2 and fgf22.
Increasing the dose of diazinon to 2 mg/kg
produced a further divergence from the effects
seen with chlorpyrifos (Figure 2B). Although
we still saw a signiﬁcant reduction in fgf20 in
the forebrain, no other gene was signiﬁcantly
affected for this region. In the brain stem, the
higher dose of diazinon produced an even
larger decrease in fgf2 expression than with
either chlorpyrifos or the lower diazinon
treatment. These regional differences between
diazinon and chlorpyrifos were statistically
significant (p < 0.02 for the interaction of
treatment × region × gene).
Two of the four genes encoding the
FGFRs, fgfr1 and fgfr4, showed statistically sig-
nificant treatment-related changes in expres-
sion, but the magnitude of the effect on fgfr1
was quite small, < 10% (Figure 3). In contrast,
Organophosphate effects on developing brain FGFs
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Table 1. Control values.
Name Gene Genbank accession no. Brainstem Forebrain
Fibroblast growth factor 1 fgf1 NM_012846 0.98 ± 0.05 1.00 ± 0.04
Fibroblast growth factor 2 fgf2 NM_019305 1.17 ± 0.09 1.02 ± 0.03
Fibroblast growth factor 3 fgf3 NM_130817 1.13 ± 0.11 0.87 ± 0.04
Fibroblast growth factor 9 fgf9 NM_012952 1.37 ± 0.08 0.81 ± 0.02*
Fibroblast growth factor 11 fgf11 NM_130816 1.03 ± 0.13 1.18 ± 0.10
Fibroblast growth factor 12 fgf12 NM_130814 1.02 ± 0.07 1.01 ± 0.03
Fibroblast growth factor 13 fgf13 NM_053428 0.97 ± 0.02 1.00 ± 0.02
Fibroblast growth factor 14 fgf14 NM_022223 0.87 ± 0.06 1.20 ± 0.04*
Fibroblast growth factor 15 fgf15 NM_130753 1.04 ± 0.15 1.15 ± 0.20
Fibroblast growth factor 17 fgf17 NM_019198 0.96 ± 0.06 1.00 ± 0.08
Fibroblast growth factor 18 fgf18 NM_019199 0.96 ± 0.04 0.99 ± 0.04
Fibroblast growth factor 20 fgf20 NM_023961 0.92 ± 0.23 1.63 ± 0.22*
Fibroblast growth factor 21 fgf21 NM_130752 0.99 ± 0.08 0.97 ± 0.07
Fibroblast growth factor 22 fgf22 NM_130751 1.11 ± 0.02 0.93 ± 0.04*
Fibroblast growth factor 23 fgf23 NM_130754 1.10 ± 0.10 0.84 ± 0.10
Fibroblast growth factor receptor 1 fgfr1 NM_024146 1.00 ± 0.02 1.08 ± 0.02*
Fibroblast growth factor receptor 2 fgfr2 BF 557.572 1.10 ± 0.04 0.96 ± 0.02*
Fibroblast growth factor receptor 3 fgfr3 NM_053429 0.98 ± 0.02 1.00 ± 0.03
Fibroblast growth factor receptor 4 fgfr4 XM_344570 0.89 ± 0.03 0.98 ± 0.03
GenBank accession numbers from GenBank (2007).
*Signiﬁcant difference between brain stem and forebrain.fgfr4 showed signiﬁcant increases in expression
for all three organophosphate treatment groups,
an effect that was restricted to the brain stem.
Diazinon produced a larger increase than did
chlorpyrifos. Again, the regional differences in
the effects of the two organophosphates were
statistically distinguishable (p < 0.05 for the
interaction of treatment × region × gene).
Earlier work with higher doses of chlorpyri-
fos administered for longer periods of time—
treatments that evoke signiﬁcant and persistent
cholinesterase inhibition and/or growth
impairment—identified small (10–20%)
decreases in the mRNA encoding nerve growth
factor (Betancourt et al. 2006). We also exam-
ined expression of the two corresponding genes
on our arrays, ngfb (GenBank accession no.
XM_227525; GenBank 2007) and ngfg
(Genbank NM_031523) but found only a
small (6%) decrease in ngfb in the forebrain
that did not achieve statistical significance
(data not shown). Similarly, we found no
significant effects on expression of the gene
encoding brain-derived neurotrophic factor
(bdnf; Genbank accession no. NM_012513;
data not shown).
Discussion
Our results show that neonatal exposure to
doses of organophosphates that are below the
threshold for any signs of systemic intoxication
or growth deﬁcits, and just at the threshold for
any detectable inhibition of cholinesterase,
nevertheless causes profound suppression of
several members of the FGF superfamily of
neurotrophic factors. Indeed, the effects for
chlorpyrifos or diazinon in the present study
are far larger than those reported previously for
other neurotrophic factors, even when the ear-
lier work involved chlorpyrifos treatments at
higher doses for longer periods, producing
much greater cholinesterase inhibition or frank
growth impairment (Betancourt and Carr
2004; Jameson et al. 2007). Furthermore, we
found a distinct regional hierarchy correspond-
ing to the maturational and anatomical differ-
ences between the brain stem and the forebrain
(Rodier 1988). The brain stem matures earlier
than the forbrain and contains a high propor-
tion of cell bodies for cholinergic, cate-
cholaminergic, and serotonergic neurons; the
forebrain develops later and contains the termi-
nal projections of these neurotransmitter sys-
tems, all of which are prominent targets for the
developmental neurotoxicity of organophos-
phates (Slotkin 1999, 2004, 2005). In keeping
with this regional specificity, fgf20 was
suppressed by chlorpyrifos or diazinon in the
forebrain, whereas the two organophosphates
differentially targeted fgf2 in the brain stem
(diazinon > chlorpyrifos). There were also
smaller effects on fgf11, fgf14, fgf22, fgfr1, and
fgfr4, each of which also displayed either a
regionally selective effect or a difference
between the two organophosphates. In con-
trast, no such regional differences were
reported for other neurotrophic factors such as
nerve growth factor or acetylcholinesterase
splice variants associated with neural damage/
repair (Betancourt and Carr 2004; Jameson
et al. 2007). Indeed, to obtain any effect on
nerve growth factor gene expression, the dose
and duration of chlorpyrifos exposure have to
be increased to the point where cholinesterase
is persistently inhibited and/or growth is
impaired; even then, there is only a small
(10–20%) decrement (Betancourt et al. 2006).
In the present study, we used lower doses and
shorter durations of exposure that caused
barely detectable cholinesterase inhibition and
no growth impairment, and found no signiﬁ-
cant deﬁcits for either nerve growth factor or
brain-derived neurotrophic factor, indicating
that selective members of the FGF superfamily
Slotkin et al.
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Figure 2. Effects of diazinon exposure on PNDs 1–4 at 1 mg/kg/day (A) or 2 mg/kg/day (B) on expression of
genes encoding the FGFs, shown as the percentage change from control values (Table 1). Multivariate
ANOVA (all genes, both regions) indicates a signiﬁcant interaction of treatment × region × gene (p < 0.003).
Error bars indicate SE.
*Signiﬁcant main treatment effect. #Signiﬁcant difference from corresponding control region after a treatment × region
difference was detected by ANOVA.
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Figure 1. Effects of 1 mg/kg/day chlorpyrifos exposure (PNDs1–4) on expression of genes encoding the
FGFs, shown as the percentage change from control values (Table 1). Multivariate ANOVA (all genes, both
regions) indicates a main effect of treatment (p < 0.05) and interactions of treatment × gene (p < 0.03) and
treatment × region × gene (p < 0.02). Error bars indicate SE.
*Signiﬁcant main treatment effect. #Signiﬁcant difference from corresponding control region after a treatment × region
difference was detected by ANOVA.
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#are indeed far more sensitive to disruption by
the organophosphates.
The regional selectivity suggests that the
effects of neonatal exposure to organo-
phosphates on expression of FGFs reﬂects the
targeting of specific processes in brain
development rather than a global interference
with neurotrophic responses. Below, we will
consider each of the FGFs in turn, emphasiz-
ing their various roles in neural development
and plasticity. However, ﬁrst it is necessary to
consider the important differences between
chlorpyrifos and diazinon. 
In the developing rat brain, treatment
with 1 mg/kg chlorpyrifos produces approxi-
mately a 10–20% inhibition of cholinesterase
(Song et al. 1997), roughly equivalent to that
seen at 2 mg/kg diazinon (Slotkin et al.
2006b); the lower dose of diazinon (1 mg/kg)
produces no signiﬁcant inhibition whatsoever
(Slotkin et al. 2006b). If the effects of these
agents were the result of cholinesterase inhibi-
tion, then the chlorpyrifos treatment should
produce the same pattern of effects as the
higher dose of diazinon, whereas the lower
diazinon dose should have no effect at all. In
fact, though, all three treatments shared the
same major suppression of fgf20 in the fore-
brain. Furthermore, the low dose of diazinon
inhibited brain stem fgf2 and fgf22 expression,
and increased fgfr4, just as did chlorpyrifos. It
is therefore apparent that these effects are
totally unrelated to cholinesterase inhibition,
the mechanism that underlies the systemic
toxicity of the organophosphates, thus rein-
forcing the concept that the developmental
neurotoxicity of these agents represents a sep-
arable set of mechanisms that operate at lower
exposures (Colborn 2006; Slotkin 1999,
2004, 2005; U.S. Environmental Protection
Agency 2006). 
It is also noteworthy that we saw several
important differences in the effects of chlor-
pyrifos as compared with diazinon: chlorpyri-
fos decreased fgf2 and fgf11 in the forebrain,
whereas diazinon did not; in the brain stem,
diazinon reduced fgf2 and induced fgfr4 much
more than did chlorpyrifos, and also had
effects on forebrain fgf14 and fgfr1 that were
not seen with chlorpyrifos. The similarities and
disparities suggest that the two organophos-
phates are likely to produce many parallels in
subsequent neurodevelopmental deficits but
may also differ in important ways. Although
much more information is available for chlor-
pyrifos than for diazinon, several findings
already suggest differential targeting of neural
cell replication, neuritic outgrowth, cytotoxic
events, and cholinergic and monoaminergic
neurotransmitter systems by these two agents
(Jameson et al. 2007; Qiao et al. 2001; Slotkin
et al. 2006a, 2007).
The two specific members of the FGF
superfamily that were most highly affected by
neonatal organophosphate exposure were fgf2
and fgf20, both of which have clearly estab-
lished roles in neurodevelopment, plasticity,
damage/repair, and neurodegenerative dis-
orders. The expression of fgf2 shows spatial
and temporal relationships to the matura-
tional profile of each brain region (Gomez-
Pinilla et al. 1994; Monfils et al. 2006) and
up-regulation of this gene is required for the
recovery from developmental brain injury
(Monﬁls et al. 2005; Yoshimura et al. 2001).
In addition, we recently found that fgf2 is inti-
mately involved in the programming of neural
plasticity associated with less injurious pertur-
bations, such as prenatal stress (Fumagalli
et al. 2005). Accordingly, the robust down-
regulation of this gene caused by neonatal
organophosphate treatment is likely to play an
important role in the neurodevelopmental
outcomes of such exposures; in particular, our
finding of regional selectivity (brain stem >
forebrain) is in keeping with the targeting of a
speciﬁc maturational stage and/or anatomical
location and similarly, the preferential sensi-
tivity to diazinon predicts a potentially wors-
ened outcome with this agent. For fgf2, our
finding of gross suppression by organophos-
phates during the brain growth spurt
(Dobbing and Sands 1979) is highly likely to
have long-term, adverse consequences for
neural development and behavioral function.
Even a brief period of fgf2 down-regulation
interferes directly with neurogenesis (Tao
et al. 1997), and the period of exposure stud-
ied here (first few days after birth) corre-
sponds to the peak proliferation period in a
number of neuronal populations, including
those of the hippocampal dentate gyrus
(Kempermann et al. 1997; Rodier 1988). If
similar effects occur with organophosphate
exposures in earlier or later developmental peri-
ods, this could explain why shifting the expo-
sure window often targets the neural cells and
regions that are undergoing the most rapid
development (Slotkin 1999, 2004, 2005).
In contrast to the organophosphate-
evoked reduction in fgf2, which was more
prominent in the brain stem, the suppression
of fgf20 was selective for the forebrain. What is
particularly notable about the regional differ-
ence is that fgf20 is preferentially expressed in
a subregion of the forebrain, the striatum
(Ohmachi et al. 2000), which contains the
majority of dopamine projections, the loss of
which results in Parkinson disease. There is
growing suspicion that repeated developmen-
tal exposures to pesticides that target striatal
dopamine projections play a signiﬁcant role in
the later emergence of this neurodegenerative
disorder (for review, see Cory-Slechta et al.
2005; Landrigan et al. 2005). Indeed, the rela-
tionship of suppressed fgf20 expression to
dopaminergic deﬁcits and thence to Parkinson
disease is directly supported by human genetic
data (Murase and McKay 2006; Takagi et al.
2005; van der Walt et al. 2004) and by the
speciﬁc role of this neurotrophic factor in pro-
moting survival of the very neurons that are
lost in Parkinson disease (Damier et al. 1999;
Yamada et al. 1990). 
The requirement for fgf20 is similarly
found for development of these neurons and
for preventing their death from apoptosis sec-
ondary to oxidative stress (Murase and
McKay 2006); the striatum is especially sensi-
tive to oxidative damage, in part because
dopamine itself produces oxidative metabo-
lites (Hirsch 1994; Olanow and Arendash
1994). Organophosphates target striatal
dopamine systems by causing release of
dopamine while simultaneously evoking
oxidative stress through other cellular mecha-
nisms (Bloomquist et al. 2002; Gupta 2004;
Jett and Navoa 2000; Karen et al. 2001;
Lazarini et al. 2004; Slotkin et al. 2002, 2005;
Slotkin and Seidler 2007). Consequently,
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Figure 3. Effects of chlorpyrifos or diazinon exposure on expression of genes encoding the FGF receptors,
shown as the percentage change from control values (Table 1). Multivariate ANOVA (all treatments, all
genes, both regions) indicates interactions of treatment × region (p < 0.005) and treatment × region × gene
(p < 0.05). Error bars indicate SE.
*Signiﬁcant main treatment effect. #Signiﬁcant difference from corresponding control region after a treatment × region
difference was detected by ANOVA.
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vulnerable to long-term damage after develop-
mental exposure to chlorpyrifos (Aldridge
et al. 2005b; Dam et al. 1999; Slotkin et al.
2002, 2007; Slotkin and Seidler 2007).
Finally, it should be noted that fgf2 is also deﬁ-
cient in dopaminergic neurons in Parkinson
disease (Tooyama et al. 1993) and fgf2 and
fgf20 actually act in concert to protect
dopaminergic neurons from oxidative injury
and to promote their repair (Krieglstein et al.
1998; Ohmachi et al. 2000; Otto and
Unsicker 1990; Shults et al. 2000), so that the
combined deficit in both these neurotrophic
factors, superimposed on organophosphate-
induced oxidative stress, may render striatal
dopamine pathways especially vulnerable. In
particular, in Parkinson disease, degeneration
begins in the brain stem (Braak et al. 2006),
the region in which we found reduced fgf2
expression after neonatal organophosphate
exposure. We therefore anticipate that later in
life, exposed individuals may show a greater
likelihood of neurodegenerative disorders such
as Parkinson disease, which is already known
to be associated with pesticide exposures in
adulthood (Kamel and Hoppin 2004).
In addition to the major changes seen for
fgf2 and fgf20 expression, we found signifi-
cant but smaller effects on other members of
the FGF superfamily, including fgf11, fgf14,
and fgf22, and also on two of the receptor
genes, fgfr1 and fgfr4. Although the roles for
these are less well understood, there is sub-
stantial evidence for involvement of all of
them in neurodevelopment and hence in the
developmental neurotoxicity of the organo-
phosphates. Developing neurons show
particularly high expression of fgf11 and fgf14
(Luo et al. 2002; Wang et al. 2000), and the
latter participates directly in neuronal signal-
ing, axonal trafficking, and development of
sodium channels required for neuronal
excitability (Lou et al. 2005; Wang et al.
2002). Deficits in fgf14 are associated with
the development of movement disorders
(Wang et al. 2002) and it is well established
that early exposure to organophosphates com-
promises the subsequent development of
motor activity (Carr et al. 2001; Dam et al.
2000). Similarly, fgf22, a recently discovered
member of the FGF family, is involved in
neural differentiation of granule cells and acts
as an organizer of presynaptic activity
(Umemori et al. 2004). Again, hippocampal
and cerebellar granule cells are known to be
targeted by developmental exposure to
organophosphates (Abdel-Rahman et al.
2003; Roy et al. 2005) in association with
profound alterations in the patterns of pre-
synaptic neuronal activity and associated
behaviors (Aldridge et al. 2005b; Dam et al.
1999; Icenogle et al. 2004; Levin et al. 2001,
2002; Qiao et al. 2003, 2004; Richardson
and Chambers 2004, 2005; Slotkin et al.
2001, 2002; Slotkin and Seidler 2007). 
Of the two FGF receptor genes for which
we found significant changes, fgfr1 is only
weakly expressed in the developing brain but
probably serves as an organization factor
(Blak et al. 2005); we found only a small
effect on this receptor, restricted to diazinon,
so that this may ultimately contribute to some
differences in outcome between the two
organophosphates. We saw a far more robust
effect on fgf4, again with a greater action of
diazinon as compared to chlorpyrifos. In con-
trast to fgfr1, fgfr4 is highly expressed in devel-
oping brain, especially in the hippocampus
(Cool et al. 2002; Limke et al. 2003; Wright
et al. 2004) and in cholinergic neurons of the
medial habenular nucleus (Miyake and Itoh
1996), and is involved specifically in neurite
outgrowth (Hart et al. 2000). Furthermore,
this receptor binds fgf2, one of the FGF mem-
bers highly affected by organophosphate expo-
sure, reinforcing the greater potential
contribution of this particular signaling path-
way; indeed, the fact that fgf4 was up-regu-
lated suggests that this is a partial, adaptive
response to the suppression of fgf2 expression,
a conclusion reinforced by the fact that diazi-
non was more effective than chlorpyrifos for
both the down-regulation of brain stem fgf2
and the up-regulation of fgfr4. In keeping
with these relationships, developmental expo-
sure to organophosphates especially targets
each of the processes associated with fgfr4:
neurons of the cholinergic phenotype (Slotkin
1999, 2004, 2005), the hippocampus (Abdel-
Rahman et al. 2003; Pung et al. 2006; Roy
et al. 2005; Terry et al. 2003), and neuritic
outgrowth (Axelrad et al. 2003; Das and
Barone 1999; Howard et al. 2005; Slotkin
et al. 2006a; Song et al. 1998).
It is important to note a number of limi-
tations of our approach, which relies on meas-
urement of gene expression at the mRNA
level assessed in two, broadly defined brain
regions. First, the magnitude of changes was
small when compared to the fold-change that
can be obtained with in vitro studies of pesti-
cide neurotoxicity, where typically one
assesses the effects on a single cell type at a
fixed stage of differentiation (Mense et al.
2006). That is hardly surprising, given the
heterogeneity of the brain stem and the fore-
brain, so that even a large change in gene
expression in a speciﬁc cell population would
be “washed out” by mRNA from unaffected
areas. In fact, treatment of animals with
higher doses of organophosphates that pro-
duce outright toxicity or even lethality rarely
produces changes in gene expression exceed-
ing 10–30% in vivo (Betancourt et al. 2006;
Damodaran et al. 2006a, 2006b). 
The second limitation is inherent in any
study of mRNA: this measure by itself does
not provide a definitive answer about the
actual rate of synthesis and degradation of the
encoded protein, the factors that actually con-
trol the concentrations of the corresponding
trophic factors or factors within the cell.
Nevertheless, there are two important aspects
designed into the current study that render
the ﬁndings relevant and interpretable. First,
we included chlorpyrifos as a test compound
whose impact has already been conﬁrmed for
the relevant end points of neural cell differ-
entiation, axonogenesis, and other develop-
mental processes known to be regulated by
FGFs. Second, our interpretations rely on
patterns of changes across multiple regions
and FGF/FGFR subtypes rather than on a
single change in one region. Nevertheless, it
is obvious that a direct mechanistic link
needs to be established between the changes
seen here at the mRNA level and the known
outcomes for chlorpyrifos, or the suspected
outcomes for diazinon. 
Our results are also limited by the fact that
we examined only males, whereas there are
numerous studies showing signiﬁcant sex dif-
ferences in the outcomes of developmental
exposure to organophosphates (Aldridge et al.
2004, 2005a, 2005b; Dam et al. 2000; Levin
et al. 2001; Ricceri et al. 2006; Slotkin 2005;
Slotkin et al. 2001, 2002; Slotkin and Seidler
2007). Here, we were limited primarily by
practical considerations of technical capabilities
and cost. We expect, however, that males and
females will show important differences in
transcriptional proﬁles in accordance with the
sex-selective nature of organophosphate-
induced neurodevelopmental anomalies.
Despite these limitations, though, our results
are likely to be relevant to environmental expo-
sures of fetuses and children to organophos-
phates. Although our studies were modeled
primarily on the upper limits of estimated or
measured exposures after home or agricultural
application (Gurunathan et al. 1998; Ostrea
et al. 2002), recent studies indicate that much
lower, long-term exposures of pregnant women
result in adverse neurodevelopmental outcomes
for their children (Eskenazi et al. 2007; Rauh
et al. 2006; Young et al. 2005). Accordingly,
modeling the potential mechanisms underlying
the adverse effects of these agents at exposures
below the threshold for cholinesterase inhibi-
tion may provide important insights into the
etiology of these orders and thus to potential
strategies for amelioration.
In conclusion, our results show that
neonatal exposure to low doses of organo-
phosphates, below the threshold for any signs
of systemic toxicity and spanning the thresh-
old for any detectable cholinesterase inhibi-
tion, evoke profound and regionally selective
effects on expression of specific members of
the FGF superfamily of neurotrophic factors,
with the largest effects seen for fgf2 and fgf20.
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notable disparities in the responses to chlor-
pyrifos and diazinon, and that robust effects
were seen at a dose of diazinon that does not
inhibit cholinesterase, supports the idea that
organophosphates differ in their propensity to
elicit developmental neurotoxicity, unrelated
to their anticholinesterase activity. Further,
the specific involvement of fgf2 and fgf20 in
development of the hippocampus and stria-
tum matches some of the most sensitive
regional targets for neurodevelopmental dis-
ruption by the organophosphates, reinforcing
the potential mechanistic role of suppression
of these neurotrophic factors in organophos-
phate-induced developmental neurotoxicity. 
The close relationship between deﬁciencies
in these factors and loss of dopamine neurons
in Parkinson disease further indicates the need
for long-term studies of the effects of early
organophosphate exposure, preferably occupy-
ing the entire life span so as to determine
whether developmental exposures lead to later
emergence of neurodegenerative disorders.
Finally, the identification of specific neuro-
trophic factors targeted by organophosphates
may enable the design of targeted, interven-
tional strategies that might prevent or offset
neurodevelopmental damage in cases of
known exposure. For example, increasing the
concentration of FGF2 protein appears to off-
set the functional outcome of neonatal dam-
age to the motor cortex (Monﬁls et al. 2005),
and the neuroprotective effect of nicotine in
animal models of Parkinson disease (Quik and
Di Monte 2001) is associated with its ability
to up-regulate fgf2 expression (Belluardo et al.
2004). The characterization of neurotrophic
factors involved in the developmental neuro-
toxicity of organophosphates thus establishes a
mechanistic link between the initial events in
neural cell damage and the eventual outcome,
while at the same time providing valuable
information to enable discrimination between
the effects of different organophosphates as
well as potential therapeutic interventions to
prevent or offset neural damage.
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